FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications By Ogkologos - August 19, 2026 126 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Investing in volunteers since 2002: The tale of time July 11, 2022 Anal Cancer Incidence and Deaths Are Rising in the United States December 19, 2019 How I Learned to Advocate for Myself During Cancer: “Your Stories”... October 18, 2022 FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma October 5, 2020 Load more HOT NEWS 10-Year Data Underscore How ICI Therapy Has Helped to Change the... ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival...
